• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

B-po02-051 atrial arrhythmia detection using insertable cardiac monitor in patients with cryptogenic stroke: a real-word cohort study
AF can be the underlying cause of cryptogenic strokes (CS). CRYSTAL-AF demonstrated that 30% developed AF by 36 months using an insertable cardiac Monitor (ICM) in patients with CS.
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Jean Jacques Noubiap, Gijo Thomas, Curtis Harper, John Leonard Fitzgerald, Kevin R. Campbell, Dennis H. Lau, Melissa E. Middeldorp, Prashanthan Sanders Source Type: research

B-po03-148 risk stratification for ischemic stroke and major bleeding in patients without atrial fibrillation - validity of cha2ds2-vasc and has-bled score
Atrial fibrillation (AF) is the most common arrhythmia. Recent cardiac implantable electronic devices (CIEDs) have led to an improvement in the early detection of AF episodes. ESC guidelines for the management of AF recommend the use of CHA2DS2-VASc score as class I to predict the risk of ischemic stroke in patients with AF. However, the validity of the CHA2DS2-VASc and HAS-BLED scores to predict ischemic stroke and major bleeding events in patients without AF remains unclear.
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Miyo Nakano, Yusuke Kondo, Masahiro Nakano, Takatsugu Kajiyama, Ryo Ito, Haruhiro Takahira, Mari Kitagawa, Masafumi Sugawara, Toshinori Chiba, Yoshio Kobayashi Source Type: research

B-po05-199 differences in stroke or systemic thromboembolism readmissions after hospitalization for atrial fibrillation or atrial flutter
Although atrial fibrillation (AF) and atrial flutter (AFL) are different arrhythmias, they are assumed to confer the same risk of stroke and systemic thromboembolism (STE) despite a lack of available evidence.
Source: Heart Rhythm - July 28, 2021 Category: Cardiology Authors: Harshith Thyagaturu, Alexander Bolton, Sittinun Thangjui, Dinesh Voruganti, Hakan Paydak Source Type: research

Early recurrence of atrial tachyarrhythmia post –atrial fibrillation ablation: Filling in the blank
Supported by the recent results of the Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) and Early Treatment of Atrial Fibrillation for Stroke Prevention (EAST-AFNET4) trials, catheter ablation is a preferable contemporary linchpin in the treatment of symptomatic atrial fibrillation (AF).1,2 Traditionally, the efficacy with ablation has been broadly defined by either objective arrhythmic recurrence such as atrial arrhythmias of over 30 seconds in duration or subjective recurrence of symptomatic arrhythmias.
Source: Heart Rhythm - June 29, 2021 Category: Cardiology Authors: Christopher A. Groh, T. Jared Bunch Tags: Editorial Commentary Source Type: research

Early recurrence of atrial tachyarrhythmia post-atrial fibrillation ablation: Filling in the blank
Supported by the recent results of the Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) and Early Treatment of Atrial Fibrillation for Stroke Prevention (EAST-AFNET4) trials, catheter ablation is a preferable contemporary linchpin in the treatment of symptomatic atrial fibrillation (AF).1,2 Traditionally, the efficacy with ablation has been broadly defined by either objective arrhythmic recurrence such as atrial arrhythmias of over 30 seconds in duration or subjective recurrence of symptomatic arrhythmias.
Source: Heart Rhythm - June 29, 2021 Category: Cardiology Authors: Christopher A. Groh, T. Jared Bunch Source Type: research

Connexin45 (GJC1) loss-of-function mutation contributes to familial atrial fibrillation and conduction disease
Atrial fibrillation (AF) represents the most common clinical cardiac arrhythmia and substantially increases the risk for cerebral stroke, heart failure and death. Although causative genes for AF have been identified, the genetic determinants for AF remain largely unclear.
Source: Heart Rhythm - January 8, 2021 Category: Cardiology Authors: Ruo-Gu Li, Ying-Jia Xu, Willy G. Ye, Yan-Jie Li, Honghong Chen, Xing-Biao Qiu, Yi-Qing Yang, Donglin Bai Source Type: research

Anticoagulation for Stroke Prevention in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Review
Atrial fibrillation is the most common arrhythmia in patients with hypertrophic cardiomyopathy with a prevalence and incidence of 23% and 3.1% respectively. The risk of thromboembolism is high in patients with hypertrophic cardiomyopathy regardless of the CHADS2VASC score. This review includes five observational studies that focused on prevention of thromboembolism in patients with hypertrophic cardiomyopathy and atrial fibrillation. These papers evaluated and compared outcomes between patients on either warfarin or direct oral anticoagulants.
Source: Heart Rhythm - October 2, 2020 Category: Cardiology Authors: M. Farhan Nasser, Sanjay Gandhi, Robert J. Siegel, Florian Rader Source Type: research

Atrial Ca2+/calmodulin-dependent protein kinase II: A druggable master switch of atrial fibrillation-associated atrial remodeling?
Atrial fibrillation (AF) is the most common arrhythmia and is associated with increased morbidity and mortality, with heart failure (HF) and thromboembolism including stroke being the major consequences.1 Thus, stroke prevention with oral anticoagulants is crucial, but highly challenging, for AF management in many patients.2,3 Although our understanding of the underlying molecular mechanisms promoting AF increased substantially over the years, contemporary approaches using drugs are only moderately effective and have substantial side effects, including proarrhythmia.
Source: Heart Rhythm - February 5, 2019 Category: Cardiology Authors: Dobromir Dobrev Tags: Editorial Commentary Source Type: research

Refining the prediction of stroke in atrial fibrillation: An elusive endeavor
Atrial fibrillation (AF), the most common sustained arrhythmia, is responsible for>20% of all strokes.1 AF-associated strokes are more severe, causing significantly greater long-term disability, accounting for greater resource utilization, and resulting in significantly higher mortality compared to non-AF strokes.2 –4 Oral anticoagulants (OACs) are the standard of care for the prevention of AF-associated stroke and systemic thromboembolism. To date, OACs are the only therapeutic intervention that has been consistently and definitively shown to improve survival in the AF population.
Source: Heart Rhythm - December 18, 2018 Category: Cardiology Authors: Jason G. Andrade, Laurent Macle Tags: Editorial Commentary Source Type: research

Refining the Prediction of Stroke in Atrial Fibrillation. An elusive endeavor
Atrial fibrillation (AF), the most common sustained arrhythmia, is responsible for>20% of all strokes.1 AF-associated strokes are more severe, causing significantly greater long-term disability, accounting for greater resource utilization, and result in significantly higher mortality when compared to non-AF strokes.2-4 Oral anticoagulants (OACs) are the standard of care for the prevention of AF-associated stroke and systemic thromboembolism. To date OACs are the only therapeutic intervention that has been consistently and definitively shown to improve survival in the AF population.
Source: Heart Rhythm - December 18, 2018 Category: Cardiology Authors: Jason G. Andrade, Laurent Macle Source Type: research

Seeing is Believing: The Importance of Continuous Monitoring to Unmask the Real-World Atrial Fibrillation Recurrence after Ablation
Atrial fibrillation (AF) is a common arrhythmia encountered in clinical practice that contribute to hemodynamic abnormalities, thromboembolic events and hospitalizations.1 The prevalence of AF is around 1% in the general population, substantially increases with age and is estimated to reach 4% in 2050.2, 3 Compared with patients without AF, patients with AF has an increased risk of dementia (hazard ratio [HR]=1.56), myocardial infarction (HR=1.62), sudden cardiac death (HR=1.83), mortality (HR=2.61), heart failure (HR=3.31) and ischemic stroke (HR=3.34).
Source: Heart Rhythm - July 28, 2018 Category: Cardiology Authors: Ting-Yung Chang, Chin-Yu Lin, Shih-Ann Chen Source Type: research

Device-Guided Anticoagulation in Atrial Fibrillation: Not yet ready for prime time
Atrial fibrillation (AF), the most common sustained arrhythmia encountered in clinical practice, is associated with a three- to five-fold increased risk of stroke (accounting for>20% of all strokes).1 Independent of age and other risk factors, AF-associated strokes are relatively more severe, causing greater resource utilization, long-term disability, and mortality compared to non-AF stroke. Oral anticoagulants (OACs) are paramount in preventing AF-associated stroke and systemic thromboembolism.
Source: Heart Rhythm - July 10, 2018 Category: Cardiology Authors: Christopher C. Cheung, Jason G. Andrade Source Type: research

Is A Little Atrial Fibrillation Still Too Much?
Atrial fibrillation (AF) is most often viewed as a dichotomous variable, one that is either entirely present or absent. Guidelines support this perspective by recommending anticoagulation based on underlying stroke risk without regard to AF “type”, duration, or burden.1 The use of cardiac monitoring, however, has allowed us to quantify AF and associate outcomes with various arrhythmia characteristics.2, 3 These types of studies have raised legitimate doubts as to whether the 30 second threshold used to define AF is associated with meaningful consequences and have created equipoise for sub-clinical AF episodes lasting minutes to hours.
Source: Heart Rhythm - February 24, 2018 Category: Cardiology Authors: Rod Passman Source Type: research

Is a little atrial fibrillation still too much?
Atrial fibrillation (AF) is most often viewed as a dichotomous variable, one that is either entirely present or absent. Guidelines support this perspective by recommending anticoagulation based on underlying stroke risk without regard to AF “type,” duration, or burden.1 The use of cardiac monitoring, however, has allowed us to quantify AF and associate outcomes with various arrhythmia characteristics.2,3 These types of studies have raised legitimate doubts as to whether the 30-second threshold used to define AF is associated with m eaningful consequences and have created equipoise for subclinical AF episodes lasting minutes to hours.
Source: Heart Rhythm - February 24, 2018 Category: Cardiology Authors: Rod Passman Tags: Editorial Commentary Source Type: research

Does CHA2DS2-VASc Score reliably predict atrial arrhythmias? Analysis of a nationwide database of Remote Monitoring data daily transmitted from Cardiac Implantable Electronic Devices
CHA2DS2-VASc is a validated score for predicting stroke in patients with atrial fibrillation (AF).
Source: Heart Rhythm - February 22, 2018 Category: Cardiology Authors: Giovanni Rovaris, Francesco Solimene, Antonio D ’Onofrio, Gabriele Zanotto, Renato P. Ricci, Tiziana Mazzella, Saverio Iacopino, Paolo Della Bella, Giampiero Maglia, Gaetano Senatore, Fabio Quartieri, Mauro Biffi, Antonio Curnis, Valeria Calvi, Antonio Source Type: research

Pages: 1  2  3  4